H.C. Wainwright lowered the firm’s price target on Theravance Biopharma (TBPH) to $15 from $27 and keeps a Buy rating on the shares. The firm cites the CYPRESS data “disappointment” for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma downgraded to Neutral from Buy at B. Riley
- Theravance Biopharma price target lowered to $21 from $40 at BTIG
- Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
- Theravance Biopharma falls 28% to $13.55 in pre-market trading
- Theravance Biopharma implements cost reduction actions after study results